Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: JS001
DRUG: JS004
DRUG: JS007
DRUG: JS015
DRUG: Irinotecan Liposome Injection
DRUG: 5-Fluorouracil (5-FU)
DRUG: Leucovorin (LV)
DRUG: Nab paclitaxel
DRUG: Gemcitabine

Sponsor

Fudan University